Skip to content

US · PTCT · BIOTECHNOLOGY

PTC Therapeutics, Inc. (PTCT) intrinsic value and stock valuation

$56.42as of 2026-11-21 · Mkt cap 6.12B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PTC Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values PTCT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PTCT’s statements →

PTC Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Warren, NJ 07080 ptcbio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.73B+35.4% 5y CAGRd
20112025
Net income
$682.6M
20112025
Free cash flow
$411.2M
20112025
Total equity
-$-205.31M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.73B$806.8M$937.8M$698.8M$538.6M
Operating income$856.5M-$-302.57M-$-439.5M-$-447.41M-$-374.44M
Net income$682.6M-$-363.3M-$-626.6M-$-559.02M-$-523.9M
EPSd$7.73M-$-4.73M-$-8.37M-$-7.79M-$-7.43M
Operating cash flow$711.2M-$-107.69M-$-158.42M-$-356.65M-$-251.33M
Capital expenditure-$-300.01M-$-74.25M-$-120.62M-$-152.46M-$-85.33M
Free cash flow$411.2M-$-181.94M-$-279.04M-$-509.11M-$-336.66M
Total assets$2.9B$1.71B$1.9B$1.71B$1.94B
Total debt$2.71B$2.47B$2.23B$1.46B$1.27B
Net debt$1.72B$1.69B$1.64B$1.18B$1.08B
Total equity-$-205.31M-$-1.1B-$-818.55M-$-347.09M$1.44M
Cash and short-term investments$1.95B$1.14B$876.7M$410.7M$773.4M
Income statement
20252024202320222021
Revenue$1.73B$806.8M$937.8M$698.8M$538.6M
Cost of revenue$71.8M$57.4M$65.5M$44.7M$32.3M
Gross profit$1.66B$749.4M$872.3M$654.1M$506.3M
Research and development expenses$455.3M$534.5M$666.6M$651.5M$540.7M
Selling, general and administrative expenses$347.1M$300.9M$332.5M$326M$285.8M
Other expenses$0.00$216.6M$312.7M$124M$54.3M
Operating expenses$802.4M$1.05B$1.31B$1.1B$880.7M
Cost and expenses$874.2M$1.11B$1.38B$1.15B$913M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$152.2M$167M$129.2M$90.9M$86M
Depreciation and amortization$38.8M$75.7M$236.6M$128.8M$64.1M
Ebitda$887.7M-$-120.46M-$-330.34M-$-367.78M-$-368.18M
Operating income$856.5M-$-302.57M-$-439.5M-$-447.41M-$-374.44M
Total other income/expenses, net-$-159.89M-$-60.55M-$-256.61M-$-140.08M-$-143.9M
Income before tax$696.6M-$-363.12M-$-696.11M-$-587.49M-$-518.34M
Income tax expense$14M$180K-$-69.51M-$-28.47M$5.56M
Net income$682.6M-$-363.3M-$-626.6M-$-559.02M-$-523.9M
Weighted average shares outstanding$79.5M$76.9M$74.8M$71.7M$70.5M
Weighted average diluted shares outstanding$88.3M$76.9M$74.8M$71.7M$70.5M
Balance sheet
20252024202320222021
Cash and short-term investments$1.95B$1.14B$876.7M$410.7M$773.4M
Net receivables$181.6M$158.6M$160.8M$155.6M$110.5M
Inventory$79.7M$23.2M$30.6M$21.8M$15.9M
Total current assets$2.27B$1.37B$1.22B$693.8M$954.4M
Property, plant and equipment, net$135.4M$117.7M$179M$175M$130M
Goodwill and intangible assets$471.1M$201.1M$461.8M$788.2M$807.2M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$624.8M$339.5M$677.1M$1.01B$983.7M
Total assets$2.9B$1.71B$1.9B$1.71B$1.94B
Accounts payable$45.5M$17.3M$6.04M$27.3M$23M
Short-term debt$585.1M$271.2M$210.3M$84.5M$219.1M
Deferred revenue$2.04M$5.5M$800K$1.35M$0.00
Total current liabilities$968.4M$581M$603.1M$406.2M$509.4M
Long-term debt$2.12B$2.2B$2.02B$1.38B$1.05B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.14B$2.22B$2.11B$1.65B$1.43B
Capital lease obligations$112.1M$103.9M$130.8M$131.9M$103.9M
Total liabilities$3.1B$2.8B$2.71B$2.05B$1.94B
Common stock$80K$80K$70K$70K$70K
Retained earnings-$-2.96B-$-3.65B-$-3.28B-$-2.66B-$-2.1B
Accumulated other comprehensive income (loss)$10.5M-$-25.89M-$-1.28M$4.8M-$-24.28M
Total equity-$-205.31M-$-1.1B-$-818.55M-$-347.09M$1.44M
Total investments$960.7M$360M$282.7M$130.9M$583.7M
Total debt$2.71B$2.47B$2.23B$1.46B$1.27B
Net debt$1.72B$1.69B$1.64B$1.18B$1.08B
Cash flow statement
20252024202320222021
Net income$682.6M-$-363.3M-$-626.6M-$-559.02M-$-523.9M
Depreciation and amortization$38.8M$75.7M$236.6M$128.8M$64.1M
Stock-based compensation$74.6M$74.6M$131.2M$110.3M$103.5M
Change in working capital-$-47.88M$102.5M-$-4M-$-85.33M-$-23.79M
Accounts receivable-$-10.15M$1.73M-$-1.54M-$-48.47M-$-44.99M
Inventory-$-53.9M$6.16M-$-8.18M-$-6.67M$1.8M
Accounts payable$0.00$0.00$0.00$27.5M$23.4M
Net cash provided by operating activities$711.2M-$-107.69M-$-158.42M-$-356.65M-$-251.33M
Investments in property, plant and equipment-$-8.86M-$-6.5M-$-28.44M-$-152.46M-$-85.33M
Acquisitions, net$0.00$0.00$0.00$128.4M$57.1M
Net cash used for investing activities-$-861.98M$44.2M-$-176.74M$290.2M$219.2M
Common stock issued$99.1M$0.00$0.00$50M$23.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$331.1M$255.9M$646.4M$168M$20.9M
Net change in cash$203M$185M$314.4M$98.7M-$-19.09M
Cash at end of period$998.3M$795.3M$610.3M$295.9M$197.2M
Operating cash flow$711.2M-$-107.69M-$-158.42M-$-356.65M-$-251.33M
Capital expenditure-$-300.01M-$-74.25M-$-120.62M-$-152.46M-$-85.33M
Free cash flow$411.2M-$-181.94M-$-279.04M-$-509.11M-$-336.66M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PTC Therapeutics, Inc.

        PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.

        CEO
        Matthew Klein
        Employees
        991
        Beta
        0.53

        Explore

        Frequently asked questions

        What is the intrinsic value of PTC Therapeutics, Inc. (PTCT)?

        PTC Therapeutics, Inc. (PTCT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PTCT undervalued?

        PTCT trades at a price of $56.42 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.